161 related articles for article (PubMed ID: 30038842)
1. Comparison of DNA demethylating and histone deacetylase inhibitors hydralazine-valproate versus vorinostat-decitabine incutaneous t-cell lymphoma in HUT78 cells.
Schcolnik-Cabrera A; Domínguez-Gómez G; Dueñas-González A
Am J Blood Res; 2018; 8(2):5-16. PubMed ID: 30038842
[TBL] [Abstract][Full Text] [Related]
2. Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.
Dueñas-Gonzalez A; Coronel J; Cetina L; González-Fierro A; Chavez-Blanco A; Taja-Chayeb L
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1433-44. PubMed ID: 25154405
[TBL] [Abstract][Full Text] [Related]
3. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
Cyrenne BM; Lewis JM; Weed JG; Carlson KR; Mirza FN; Foss FM; Girardi M
Blood; 2017 Nov; 130(19):2073-2083. PubMed ID: 28972015
[TBL] [Abstract][Full Text] [Related]
4. Mass spectrometry and DigiWest technology emphasize protein acetylation profile from Quisinostat-treated HuT78 CTCL cell line.
Méhul B; Perrin A; Grisendi K; Galindo AN; Dayon L; Ménigot C; Rival Y; Voegel JJ
J Proteomics; 2018 Sep; 187():126-143. PubMed ID: 30012418
[TBL] [Abstract][Full Text] [Related]
5. Functional Depletion of HSP72 by siRNA and Quercetin Enhances Vorinostat-Induced Apoptosis in an HSP72-Overexpressing Cutaneous T-Cell Lymphoma Cell Line, Hut78.
Fujii K; Idogawa M; Suzuki N; Iwatsuki K; Kanekura T
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681913
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells.
Sung JJ; Ververis K; Karagiannis TC
J Photochem Photobiol B; 2014 Feb; 131():104-12. PubMed ID: 24518645
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
Rivera-Del Valle N; Cheng T; Irwin ME; Donnella H; Singh MM; Chandra J
Cancer Chemother Pharmacol; 2018 Mar; 81(3):483-495. PubMed ID: 29313067
[TBL] [Abstract][Full Text] [Related]
9. Influence of Histone Deacetylase Inhibitors and DNA-Methyltransferase Inhibitors on the NK Cell-Mediated Lysis of Pediatric B-Lineage Leukemia.
Pfeiffer MM; Burow H; Schleicher S; Handgretinger R; Lang P
Front Oncol; 2013; 3():99. PubMed ID: 23641363
[TBL] [Abstract][Full Text] [Related]
10. Targeting histone deacetylases in T-cell lymphoma.
Moskowitz AJ; Horwitz SM
Leuk Lymphoma; 2017 Jun; 58(6):1306-1319. PubMed ID: 27813438
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic Regulation of Host Defense Peptide Synthesis: Synergy Between Histone Deacetylase Inhibitors and DNA/Histone Methyltransferase Inhibitors.
Whitmore MA; Li H; Lyu W; Khanam S; Zhang G
Front Immunol; 2022; 13():874706. PubMed ID: 35529861
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
13. The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin.
Moyal L; Feldbaum N; Goldfeiz N; Rephaeli A; Nudelman A; Weitman M; Tarasenko N; Gorovitz B; Maron L; Yehezkel S; Amitay-Laish I; Lubin I; Hodak E
PLoS One; 2016; 11(1):e0146115. PubMed ID: 26752418
[TBL] [Abstract][Full Text] [Related]
14. BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition.
Kim SR; Lewis JM; Cyrenne BM; Monico PF; Mirza FN; Carlson KR; Foss FM; Girardi M
Oncotarget; 2018 Jun; 9(49):29193-29207. PubMed ID: 30018745
[TBL] [Abstract][Full Text] [Related]
15. Targeting Epigenetic Modifiers Can Reduce the Clonogenic Capacities of Sézary Cells.
Chebly A; Prochazkova-Carlotti M; Idrissi Y; Bresson-Bepoldin L; Poglio S; Farra C; Beylot-Barry M; Merlio JP; Tomb R; Chevret E
Front Oncol; 2021; 11():775253. PubMed ID: 34765562
[TBL] [Abstract][Full Text] [Related]
16. Response to hydralazine-valproate in a patient with mycosis fungoides.
Dueñas-Gonzalez A; Vega MT; Martinez-Baños D; García-Hidalgo L; Sobrevilla P
Case Rep Med; 2010; 2010():657579. PubMed ID: 20339522
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylases and epigenetic therapies of hematological malignancies.
Mercurio C; Minucci S; Pelicci PG
Pharmacol Res; 2010 Jul; 62(1):18-34. PubMed ID: 20219679
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.
Su Y; Hopfinger NR; Nguyen TD; Pogash TJ; Santucci-Pereira J; Russo J
J Exp Clin Cancer Res; 2018 Dec; 37(1):314. PubMed ID: 30547810
[TBL] [Abstract][Full Text] [Related]
19. AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair.
Moyal L; Goldfeiz N; Gorovitz B; Rephaeli A; Tal E; Tarasenko N; Nudelman A; Ziv Y; Hodak E
Invest New Drugs; 2018 Feb; 36(1):1-9. PubMed ID: 28884410
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds.
Blanquart C; François M; Charrier C; Bertrand P; Gregoire M
Curr Cancer Drug Targets; 2011 Oct; 11(8):919-28. PubMed ID: 21762083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
